Galinpepimut-S (WT1)

Galinpepimut-S is an investigational cancer vaccine that trains the immune system to recognize and attack cells displaying the Wilms' Tumor 1 (WT1) protein. WT1 is overexpressed on the surface of most mesothelioma tumors, making it an attractive target. The vaccine is given as a series of injections, often combined with an immune-boosting agent, and is being studied as maintenance therapy after standard treatment.

Origin

Galinpepimut-S was developed at Memorial Sloan Kettering Cancer Center by Dr. David Scheinberg and colleagues, and later advanced by SELLAS Life Sciences. The compound is a synthetic four-peptide mixture derived from the WT1 protein, first identified in the 1990s as a target overexpressed in leukemia and several solid tumors, including mesothelioma.

Significance in Asbestos Context

For mesothelioma patients, Galinpepimut-S represents one of the few targeted immunotherapies developed specifically with this disease in mind. A randomized Phase II trial at Memorial Sloan Kettering showed that patients with malignant pleural mesothelioma who received the vaccine after surgery and chemotherapy lived longer than those who did not, which led to expanded studies. Because mesothelioma has few effective second-line treatments, eligibility for a WT1 vaccine trial may meaningfully expand a patient's options. Documented enrollment in such a trial can also become relevant to a legal claim, both as evidence of the seriousness of treatment and as a category of medical expense and travel cost.

Example Sentence

After completing pemetrexed-cisplatin chemotherapy, she asked her oncologist whether she might qualify for a Galinpepimut-S (WT1) maintenance trial before her disease progressed.

Related Terms

Mesothelioma, Immunotherapy, WT1 Protein, Cancer Vaccine, Maintenance Therapy, Clinical Trial

Notes

• Ask your oncologist whether your tumor has been tested for WT1 expression by immunohistochemistry; most mesotheliomas are positive, but confirmation is usually required for trial enrollment.
• Search ClinicalTrials.gov for "Galinpepimut-S" and "mesothelioma" to find currently enrolling sites, and ask your treating team to make a referral if a trial looks appropriate.
• Keep records of trial participation, travel, lodging, and out-of-pocket costs. These can be reimbursable damages in an asbestos claim.
• Trials typically require adequate organ function and a defined window after prior treatment; do not delay asking, because eligibility windows close quickly.
• This vaccine is investigational and is not a substitute for standard-of-care surgery, chemotherapy, or approved immunotherapy regimens such as nivolumab plus ipilimumab.